Innoviva develops biopharmaceutical drugs in the respiratory, antibiotic, and digestive realms, with a focus on bringing new medicines to patients in areas of unmet need. The company collaborates with GlaxoSmithKline and receives funding from them. Innoviva's portfolio is anchored by respiratory assets, including RELVAR/BREO ELLIPTA and ANORO ELLIPTA, and the company is eligible to receive associated royalty revenues from these products. Additionally, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance BioPharma, Inc.